ENHERTU Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive ...

Daiichi Sankyo and AstraZeneca have received priority review from the US Food and Drug Administration (FDA) for the ...

AstraZeneca ( NASDAQ: AZN) and Daiichi Sankyo have received priority review from the FDA for their supplemental marketing application for Enhertu in combination with pertuzumab, marketed by Roche ( ...

Cambridge: AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab ...

The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adults ...

Enhertu plus pertuzumab granted Priority Review in US as 1st-line treatment for patients with HER2-positive metastatic breast cancer: Cambridge, UK Thursday, September 25, 2025, 0 ...

(Alliance News) - Daiichi Sankyo Co Ltd and AstraZeneca PLC on Wednesday said the US Food & Drug Administration has granted priority review for Enhertu in combination with pertuzumab as a first-line ...

Merck MRK and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III HERTHENA-Breast04 study evaluating their investigational HER3-directed DXd antibody-drug conjugate (ADC) ...

The U.S. Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application for ...

The FDA has granted priority review to the supplemental biologics license application (sBLA) of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the first-line treatment of patients with ...

Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu as a second-line therapy for HER2-positive metastatic breast ...

Jiangsu Hengrui Pharmaceuticals’ dealmaking spree rolls on, with a potential $1.1 billion transaction on a rival to AstraZeneca and Daiichi Sankyo’s blockbuster Enhertu being the latest addition.